H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $105 from $100 and keeps a Buy rating on the shares after the FDA approved an expanded indication for Imcivree to treat patients living with acquired hypothalamic obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals selects Pantherx Rare as pharmacy for Imcivree
- Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy
- Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA
- Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
- Rhythm Pharmaceuticals price target raised to $142 from $131 at Citi